Meglumine antimoniate is more effective than sodium stibogluconate in the treatment of cutaneous leishmaniasis


Yesilova Y., Surucu H. A. , Ardic N., Aksoy M., Yeşilova A., Oghumu S., ...More

JOURNAL OF DERMATOLOGICAL TREATMENT, vol.27, no.1, pp.83-87, 2016 (Peer-Reviewed Journal) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 27 Issue: 1
  • Publication Date: 2016
  • Doi Number: 10.3109/09546634.2015.1054778
  • Journal Name: JOURNAL OF DERMATOLOGICAL TREATMENT
  • Journal Indexes: Science Citation Index Expanded, Scopus
  • Page Numbers: pp.83-87

Abstract

Sodium stibogluconate (SSG, Pentostam) and meglumine antimoniate (MA, Glucantime) are two antimonials that are widely used to treat cutaneous leishmaniasis (CL), but the relative efficacies of these treatments are not clear. The aim of this study is to compare the efficacy of intralesional SSG with intralesional MA therapy in the treatment of CL. One month after completion of the therapy, 1431 of 1728 patients (82%) who received intralesional MA showed complete clinical cure compared to 1157 of 1728 patients (67%) in the SSG group. Patients who did not respond to the first round of therapy were re-administered the same treatment but with twice weekly injections. Following completion of the second course of therapy, 237 of 297 patients (80%) in the MA group and 407 of 561 patients (72%) in the SSG group healed their lesions by 1-month post-treatment. At both times, the differences in cure rates between MA and SSG groups were statistically significant (p<0.05). Cure rates in the MA group were always significantly higher than SSG groups irrespective of other parameters including age, gender, lesion site and type of lesion. Intralesional MA is more effective than intralesional SSG in the treatment of CL.